These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 6112126)

  • 21. Oral tardive dyskinesia in the rat.
    Sundén-Kuronen B; Pohto P; Alanen E
    Acta Odontol Scand; 1983 Dec; 41(6):343-8. PubMed ID: 6581673
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Differential striatal levels of TNF-alpha, NFkappaB p65 subunit and dopamine with chronic typical and atypical neuroleptic treatment: role in orofacial dyskinesia.
    Bishnoi M; Chopra K; Kulkarni SK
    Prog Neuropsychopharmacol Biol Psychiatry; 2008 Aug; 32(6):1473-8. PubMed ID: 18554768
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of neuroleptic withdrawal on plasma prolactin: a possible marker of receptor adaptation.
    Kirkpatrick B; Buchanan RW; Maeda K; Carpenter WT; Jauch D; Tamminga CA
    Biol Psychiatry; 1989 Jun; 26(2):131-8. PubMed ID: 2567610
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of neuroleptics and of potential new antipsychotic agents (MJ 13859-1 and MJ 13980-1) on a monkey model of tardive dyskinesia.
    Kovacic B; Ruffing D; Stanley M
    J Neural Transm; 1986; 65(1):39-49. PubMed ID: 2870130
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Neuroleptic-induced supersensitivity psychosis: retrospective study of schizophrenic inpatients.
    Hunt JI; Singh H; Simpson GM
    J Clin Psychiatry; 1988 Jul; 49(7):258-61. PubMed ID: 2899071
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Neuroleptic-induced supersensitivity psychosis in patients with bipolar affective disorder.
    Steiner W; Laporta M; Chouinard G
    Acta Psychiatr Scand; 1990 May; 81(5):437-40. PubMed ID: 1972608
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of acute and long-term typical or atypical neuroleptics on morphine-induced behavioural effects in mice.
    Hollais AW; Patti CL; Zanin KA; Fukushiro DF; Berro LF; Carvalho RC; Kameda SR; Frussa-Filho R
    Clin Exp Pharmacol Physiol; 2014 Mar; 41(3):255-63. PubMed ID: 24471703
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Neuroleptic-induced supersensitivity psychosis, the "hump course," and tardive dyskinesia.
    Chovinard G; Jones B
    J Clin Psychopharmacol; 1982 Apr; 2(2):143-4. PubMed ID: 6122695
    [No Abstract]   [Full Text] [Related]  

  • 29. Inhibition of neuroleptic-induced dopamine receptor supersensitivity by cyclo (Leu-Gly).
    Bhargava HN; Ritzmann RF
    Pharmacol Biochem Behav; 1980 Nov; 13(5):633-6. PubMed ID: 7443732
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Protective effect of rutin, a polyphenolic flavonoid against haloperidol-induced orofacial dyskinesia and associated behavioural, biochemical and neurochemical changes.
    Bishnoi M; Chopra K; Kulkarni SK
    Fundam Clin Pharmacol; 2007 Oct; 21(5):521-9. PubMed ID: 17868205
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Long term treatment of tardive dyskinesia.
    Jus A; Jus K; Fontaine P
    J Clin Psychiatry; 1979 Feb; 40(2):72-7. PubMed ID: 33156
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Animal models for tardive dyskinesia: effects of thioridazine.
    Sayers AC; Bürki HR; Ruch W; Asper H
    Pharmakopsychiatr Neuropsychopharmakol; 1977 Sep; 10(5):291-5. PubMed ID: 616929
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tardive dyskinesia and the behavioral consequences of chronic neuroleptic treatment.
    Gualtieri CT; Guimond M
    Dev Med Child Neurol; 1981 Apr; 23(2):255-9. PubMed ID: 6111511
    [No Abstract]   [Full Text] [Related]  

  • 34. Tardive dyskinesia presenting as gastrointestinal disorder.
    Goldberg RJ; Morris PL; Lidofsky S
    J Clin Psychiatry; 1990 Jun; 51(6):253-4. PubMed ID: 1971823
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of chronic administration of neuroleptic and anticholinergic agents on densities of D2 dopamine and muscarinic cholinergic receptors in rat striatum.
    Boyson SJ; McGonigle P; Luthin GR; Wolfe BB; Molinoff PB
    J Pharmacol Exp Ther; 1988 Mar; 244(3):987-93. PubMed ID: 2908050
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Neuropeptide-dopamine interactions. III. Cyclo(His-Pro) and persistence of dopaminergic supersensitivity on withdrawal from one year continuous neuroleptic treatment.
    Prasad C
    Schizophr Res; 1988; 1(6):411-5. PubMed ID: 2908706
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Neuroleptic drugs and their action on different neuronal pathways.
    Ungerstedt U; Herrera-Marschitz M; Forster C
    J Clin Psychiatry; 1985 Apr; 46(4 Pt 2):34-7. PubMed ID: 2858478
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Coexistence of severe parkinsonism and tardive dyskinesia as side effects of neuroleptic therapy.
    Bitton V; Melamed E
    J Clin Psychiatry; 1984 Jan; 45(1):28-30. PubMed ID: 6141157
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Phenytoin potentiation of neuroleptic-induced dyskinesias.
    Sethi KD; Hitri A; Diamond BI
    Mov Disord; 1990; 5(4):325-7. PubMed ID: 2147979
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Haloperidol (but not ziprasidone) withdrawal potentiates sensitization to the hyperlocomotor effect of cocaine in mice.
    Fukushiro DF; Carvalho Rde C; Ricardo VP; Alvarez Jdo N; Ribeiro LT; Frussa-Filho R
    Brain Res Bull; 2008 Sep; 77(2-3):124-8. PubMed ID: 18721669
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.